Form 4: Gain Therapeutics Director Acquires 15,000 Stock Options
SEC Form 4 Filing
Director Hans Peter Hasler acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
Summary
- On June 24, 2024, Hans Peter Hasler, a director of Gain Therapeutics, Inc., acquired 15,000 stock options.
- The exercise price of these options is $1.29.
- The options vest in 12 equal monthly installments starting July 24, 2024, contingent upon continuous service.
- The options expire on June 24, 2034.
- Following the transaction, Hasler directly owns 15,000 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director.
Industry Context
This is a standard disclosure related to insider transactions, common for publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director can signal confidence in the company's future prospects, potentially impacting shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/24/2024 | Date of transaction: Director acquired 15,000 stock options. |
| 07/24/2024 | Vesting start date: Options vest in 12 equal monthly installments commencing on this date. |
| 06/24/2034 | Expiration date: Stock options expire on this date. |
| 06/26/2024 | Date of report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.